Applied Drug Research Clinical Trials and Regulatory Affairs
September 14, 2026
A S Shikha, Jignesh Shah, Darshil B. Shah et al.
Introduction: Psychedelic-assisted therapy has resurfaced as a promising intervention for treatment-resistant psychiatric disorders. However, regulatory pathways differ considerably across countries because of social, ethical, legal, and political factors. Methods: This review was conducted using the regulatory frameworks of Australia, Brazil, and the USA, along with publicly accessible data,...
medRxiv
September 10, 2026
Mori Krantz, Mark C. Haigney, Mary Ross Southworth et al.
preprint
Background: Several Schedule I substances have demonstrated potential benefits for refractory psychiatric conditions and addiction. Some have been legalized at the state level, while others like kratom (mitragynine) are available over-the-counter in some states and illegal in others. A recent presidential executive order directs certain federal agencies to accelerate development and facilitate...
The International Journal of Neuropsychopharmacology
September 9, 2026
Katarzyna Henke‐Ciążyńska, Daniel Pankowski, Bartosz Helfer
Abstract Background Systematic reviews with meta-analyses (SR-MAs) of psychedelic-assisted psychotherapy (PAP) guide clinical and policy decisions. Their trustworthiness depends, in part, on how consistently different SR-MAs assess risk of bias (RoB) in the same underlying randomized controlled trials (RCTs), and how transparently those judgments are justified. Aims & Objectives To summarise...
The International Journal of Neuropsychopharmacology
September 9, 2026
Gabriella Gobbi
Abstract Background While the monoaminergic hypothesis has long dominated the treatment of mood disorders, its limitations have prompted the exploration of alternative mechanisms. Early work by Skolnick et al. (1996) demonstrated that chronic antidepressant treatment induces adaptive changes in N-methyl-D-aspartate (NMDA) receptors, suggesting glutamatergic signaling as a convergent pathway in...
Nutricion hospitalaria
September 2, 2026
Ignacio Jiménez Hernando, Mónica Gómez-Gordo Hernanz, Marta Pérez Noguero et al.
Introduction: hyponatremia is one of the most common electrolyte disorders in clinical practice and requires accurate diagnosis to prevent potentially severe neurological complications. Case report: we report the case of an 18-year-old male with no significant medical history who presented with severe headache, nausea, vomiting, and mild neurological symptoms, and was found to have severe...
Current Addiction Reports
September 2, 2026
Kathryn Fletcher, Jack Freestone, Nadine Ezard et al.
Abstract Purpose of Review Psychedelic-assisted therapy (PAT) has re-emerged as a potential intervention for substance use disorders (SUDs), yet the psychological mechanisms underlying behaviour change remain poorly synthesised. This scoping review mapped and evaluated proposed psychological processes underpinning PAT in adults with SUDs. Recent Findings Peer-reviewed English-language empirical...
Cureus
September 2026
Robert B. Raffa
An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent (such as ibogaine) therapies. The FDA issued Commissioner's National Priority Vouchers to psilocybin developers, and cleared the investigational new drug (IND) application for noribogaine hydrochloride for alcohol use disorder. These...
Neuroscience Applied
September 1, 2026
Carolina Seybert, Ana Matos Pires, Luís Madeira et al.
The therapeutic benefits of psychedelics for neuropsychiatric conditions have gathered significant attention in Europe and around the world, with treatments using psilocybin, MDMA, and ketamine as notable examples. However, the mind-altering effects of these substances, and the complexity of their regulatory frameworks, both within and outside of therapeutic use, imply careful clinical...
Clinical Neuropsychopharmacology and Addiction
September 1, 2026
Beatrice Dal Bianco, Matteo Buonarroti, Alessandro Lo Jacono et al.
Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based,...
International Journal of Innovative Technologies in Social Science
August 31, 2026
Anna Szeszko, Weronika Maria Czernek, Magdalena Cichorzewska et al.
Psychedelic-assisted therapy has emerged as a prominent area for psychiatric investigation particularly with regards to treatment-resistant depression and Post Traumatic Stress Disorder (PTSD). The purpose of this narrative review was to outline the current body of research regarding psychedelic and psychedelic-like compounds in these two psychiatric conditions highlighting psilocybin-assisted...